Our recent growth has enabled the Division to expand its research efforts. The Division is a member of the Pediatric Rheumatology Collaborative Study Group (PRCSG), a consortium of pediatric rheumatology programs across North America that participate in multicenter therapeutic trials, often, but not exclusively, industry sponsored. Studies are periodically initiated and the Division participates based on target population appropriateness. Membership in CARRA (Childhood Arthritis and Rheumatology Research Alliance) also provides networking with other North American pediatric rheumatology centers for research collaboration.
In addition, studies of pediatric rheumatology patients are underway to monitor long-term efficacy and adverse effects of adalimumab; to utilize ultrasound and Doppler to characterize growth plate anatomy in children with asymmetric juvenile arthritis including comparison with contralateral, uninvolved joints; and investigate the therapeutic effect of low and high dose Vitamin D administration in patients with systemic lupus erythematosus. Funding for these projects come from NIH, industry and some intramural in-kind support.
On the other end of the spectrum, our laboratory work involves the development of mouse models to understand the pathophysiology of inflammatory arthritis with the goal of identifying markers of emerging and evolving synovitis to be translated to the clinical realm.